| Jan'20 | Oct'19 | Jul'19 | Apr'19 | Jan'19 | Oct'18 | Jul'18 | Apr'18 | Jan'18 | Oct'17 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities | |||||||||
Net Loss | |||||||||
-1,328 | -1,652 | -2,411 | -1,147 | -701 | -665 | - | - | -723 | -9,328 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
473 | 466 | 483 | 436 | 431 | 429 | - | - | - | 425 |
Deferred income taxes | |||||||||
11 | 1 | 5 | -9 | 25 | -40 | 8 | 14 | -1 | 8,838 |
Interest income | |||||||||
- | - | - | - | - | - | - | - | - | -104 |
Net gain on sales of marketable securities | |||||||||
- | - | 0 | 0 | 7 | 323 | - | - | - | 0 |
Unrealized (gain) loss on investments - Hedge Funds | |||||||||
557 | -37 | - | - | - | - | - | - | - | - |
Provision for doubtful accounts | |||||||||
0 | 48 | - | - | - | - | - | - | - | - |
Non-cash compensation | |||||||||
317 | 94 | 103 | 97 | 142 | 30 | - | - | - | 606 |
Amortization of debt discount | |||||||||
0 | 54 | - | - | - | - | - | - | - | - |
Realized gain on disposal of bonus shares | |||||||||
- | - | - | - | - | - | 0 | 0 | 0 | 246 |
Change in assets and liabilities: | |||||||||
Trade accounts receivable | |||||||||
96 | -173 | -186 | 393 | -14 | 92 | -119 | 180 | -126 | 88 |
Prepaid expenses and other current assets | |||||||||
36 | -217 | -333 | 233 | 123 | 63 | -134 | 332 | 66 | -6 |
Other assets | |||||||||
-251 | 289 | -455 | 98 | 69 | 13 | 231 | 95 | 120 | 140 |
Accounts payable and accrued expenses | |||||||||
-56 | -196 | 442 | -205 | 434 | -138 | -258 | 146 | -2 | 79 |
Due to Related Party | |||||||||
- | -37 | - | - | - | 171 | 388 | -184 | 58 | -260 |
Due to/from related parties | |||||||||
34 | -160 | - | - | - | - | - | - | - | - |
Other current liabilities | |||||||||
- | -12 | 8 | -44 | 45 | -6 | -2 | 7 | 10 | -25 |
Other liabilities | |||||||||
- | - | - | - | -1 | -14 | - | - | - | - |
Other liabilities | |||||||||
- | - | - | - | - | - | 118 | -25 | 25 | 0 |
Net cash used in operating activities | |||||||||
-964 | -936 | -594 | -1,639 | -175 | -724 | -745 | -1,111 | 70 | -29 |
Investing activities | |||||||||
Purchases of property and equipment | |||||||||
135 | 321 | 35 | 306 | 32 | 26 | 138 | -156 | 505 | 223 |
Proceeds from sale and maturity of marketable securities, net | |||||||||
- | - | 0 | 0 | 19,211 | 5,820 | - | - | - | 0 |
Purchase of marketable securities | |||||||||
- | - | - | - | - | 953 | - | - | - | - |
Investment in Rafael Pharmaceuticals | |||||||||
- | - | - | - | 45,870 | 10,000 | 151 | 0 | 0 | 0 |
Investment in Rafael Pharmaceuticals | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Net cash used in investing activities | |||||||||
-135 | -321 | -35 | -306 | -25,738 | -5,159 | 4,245 | 592 | -505 | -223 |
Financing activities | |||||||||
Proceeds from exercise of options | |||||||||
- | - | 0 | 27 | 45 | 118 | - | - | - | 0 |
Net cash (used in) provided by financing activities | |||||||||
- | - | 35 | 27 | 30,709 | 118 | 1,750 | -900 | 900 | 0 |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
-34 | 4 | -351 | 118 | -113 | 48 | -58 | 16 | 24 | 15 |
Net decrease in cash and cash equivalents | |||||||||
-1,249 | -1,253 | -945 | -1,800 | 4,683 | -5,717 | 5,198 | -1,403 | 489 | -237 |
Supplemental Schedule of Non-Cash Investing and Financing Activities | |||||||||
Adoption effect of ASU 2016-01 | |||||||||
- | - | 0 | 0 | 0 | 39 | - | - | - | 0 |
Conversion of LipoMedix Bridge Note | |||||||||
118 | 82 | - | - | - | - | - | - | - | - |
Conversions of related party convertible notes payable and accrued interest | |||||||||
0 | 15,668 | - | - | - | - | - | - | - | - |